Botulinum toxin as a novel therapeutic approach for auriculotemporal neuralgia

被引:5
作者
Pinto, Maria J. [1 ,2 ]
Guerrero, Angel L. [3 ,4 ]
Costa, Andreia [1 ,2 ]
机构
[1] Ctr Hosp Univ Sao Joao, Dept Neurol, EPE, Porto, Portugal
[2] Fac Med Univ Porto, Dept Clin Neurosci & Mental Hlth, Porto, Portugal
[3] Hosp Clin Univ, Dept Neurol, Headache Unit, Valladolid, Spain
[4] Univ Valladolid, Dept Med, Valladolid, Spain
来源
HEADACHE | 2021年 / 61卷 / 02期
关键词
anesthetic nerve block; auriculotemporal neuralgia; botulinum toxin; follow-the-pain;
D O I
10.1111/head.14043
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objectives/Background: Auriculotemporal neuralgia is a rare headache disorder. Anesthetic nerve blockade seems to be effective in most cases; however, literature is scarce about the management of refractory cases. Methods: Case report. Results: We report a 44-year-old woman with migraine without aura presented with moderate-to-severe right temporoparietal headache. The pain was refractory to multiple pharmacological strategies, including intravenous analgesia. A more throughout examination lead to the diagnosis of auriculotemporal neuralgia and anesthetic nerve blocks were performed. Due to early pain recrudescence, botulinum toxin (BoNT) was tried with better and longstanding pain control. Conclusion: BoNT may be a useful treatment option in refractory auriculotemporal neuralgia. The best approach is yet to be established; however, the "follow-the-pain" protocol may be a reasonable option.
引用
收藏
页码:392 / 395
页数:4
相关论文
共 14 条
[1]   Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A [J].
Aoki, KR .
NEUROTOXICOLOGY, 2005, 26 (05) :785-793
[2]   European Academy of Neurology guideline on trigeminal neuralgia [J].
Bendtsen, L. ;
Zakrzewska, J. M. ;
Abbott, J. ;
Braschinsky, M. ;
Di Stefano, G. ;
Donnet, A. ;
Eide, P. K. ;
Leal, P. R. L. ;
Maarbjerg, S. ;
May, A. ;
Nurmikko, T. ;
Obermann, M. ;
Jensen, T. S. ;
Cruccu, G. .
EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 (06) :831-849
[3]   The treatment of occipital neuralgia: Review of 111 cases [J].
Finiels, P. -J. ;
Batifol, D. .
NEUROCHIRURGIE, 2016, 62 (05) :7-14
[4]   Observational, open-label, non-randomized study on the efficacy of onabotulinumtoxinA in the treatment of nummular headache: The pre-numabot study [J].
Garcia-Azorin, David ;
Trigo-Lopez, Javier ;
Sierra, Alvaro ;
Blanco-Garcia, Laura ;
Martinez-Pias, Enrique ;
Martinez, Blanca ;
Talavera, Blanca ;
Guerrero, Angel L. .
CEPHALALGIA, 2019, 39 (14) :1818-1826
[5]  
Kapural Leonardo, 2007, Pain Pract, V7, P337, DOI 10.1111/j.1533-2500.2007.00150.x
[6]   Botulinum Toxin Type A as a Therapeutic Agent against Headache and Related Disorders [J].
Luvisetto, Siro ;
Gazerani, Parisa ;
Cianchetti, Carlo ;
Pavone, Flaminia .
TOXINS, 2015, 7 (09) :3818-3844
[7]   Other facial neuralgias [J].
O'Neill, Francis ;
Nurmikko, Turo ;
Sommer, Claudia .
CEPHALALGIA, 2017, 37 (07) :658-669
[8]   Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition [J].
Olesen, Jes .
CEPHALALGIA, 2018, 38 (01) :1-211
[9]  
Pareja JA., 2003, J HEADACHE PAIN, V4, P125, DOI DOI 10.1007/s10194-003-0046-5
[10]   Current Status and Future Directions of Botulinum Neurotoxins for Targeting Pain Processing [J].
Pellett, Sabine ;
Yaksh, Tony L. ;
Ramachandran, Roshni .
TOXINS, 2015, 7 (11) :4519-4563